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Introduction
Maple syrup urine disease (MSUD), tyrosinaemia and phenylketonuria (PKU) are severe inborn errors of amino acid metabolism, which if untreated, can have catastrophic consequences for the patient. MSUD results from a genetic defect of the branched-chain a-ketoacid dehydrogenase enzyme system. This metabolic defect is characterized by an accumulation of branched-chain a-ketoacids and their respective branched-chain amino acids, leucine, isoleucine, alloisoleucine and valine and is associated with severe ketoacidosis during periods of metabolic decompensation. 1 PKU is the result of a de¢ciency in phenylalanine hydroxylase, the enzyme responsible for converting phenylalanine to tyrosine, which if untreated, results in severe mental retardation in a¡ected individuals and in toxic embryopathy with congenital malformations, microcephaly and impaired cognitive development in o¡spring of poorly controlled pregnant women with PKU. 2 PKU is characterized by abnormal accumulation of phenylalanine and reduced concentrations of tyrosine. Hereditary tyrosinaemia type 1 is associated with liver and kidney failure and markedly elevated blood concentrations of tyrosine. Methionine concentrations are also frequently measured on a routine basis for monitoring patients with homocystinuria due to cystathionine b-synthase de¢ciency. Therapeutic dietary intervention of all four diseases requires speci¢c measurement of these amino acids in blood often on a frequent basis. In our own practice in eastern Pennsylvania the frequency of MSUD is high and acute patient management frequently necessitates urgent measurement of branched-chain amino acids to determine therapeutic needs. Consequently, we needed to develop a high throughput and sensitive assay for these amino acids. In addition, we recognize that faster throughput of samples would allow results on patients with PKU and tyrosinaemia to be available in a more timely manner so that dietary adjustments could be made while in the clinic.
There are a number of chromatographic methods for the separation and estimation of plasma amino acids. Most methods exploit ion-exchange chromatography or high-performance liquid chromatography (HPLC) with pre-or post-column derivatization in order to detect amino acids spectrophotometrically. 3 In recent years, HPLC methods have undergone technical improvements, which have resulted in modest reduction in analytical time. Vollmer et al. 4 described a rapid isocratic reversephase HPLC that could analyse phenylalanine, tryptophan and the branched-chain amino acids in a 12 min run which was applied to monitoring PKU patients. Various derivatizing reagents, such as £uorescamine, 5 o-phthalaldehyde (OPA), 4,6,7 dabsyl chloride, 8 phenylthiohydanthion, 9 7-£uoro-4-nitrobenzo-2-oxa-1,3diazole (NBD-F) 10 and 9-£uorenylmethylchloroformate (FMOC), 11 have been developed for amino acid quantitation but all of these are subject to interference. More recently HPLC methods have been linked to mass spectrometric (MS) detectors, which are able to provide positive peak identi¢cation. 12--14 However, amino acid analysis using ion-exchange chromatography or HPLC remains a time-consuming process irrespective of detection systems and long analysis times which include calibrators, standards and controls make urgent sample analysis challenging, particularly if there are multiple stat specimens at any given time. We have developed a rapid assay for amino acid analysis for MSUD, tyrosinaemia and PKU using ultra-performance liquid chromatography (UPLC)tandem mass spectrometry (MS/MS) and present our ¢ndings here.
Methods

Patient samples
We obtained 75 anonymized plasma samples from 41 patients with either MSUD or PKU, and 34 controls with neither disease but for whom amino acid analysis was requested and reported as normal. Samples from patients with tyrosinaemia type 1 or homocystinuria were not available during the course of this study but normal concentrations of tyrosine and methionine were compared. The samples were analysed using the UPLC-MS/MS technique described below and on a Beckman 6300 amino acid analyser (AAA), which has been the routine analytical system in this clinical laboratory for over 20 years (Beckman Instruments, Brea, CA, USA). Venous blood was collected in sodium heparin and centrifuged at 900 g for 5 min at 41C. The plasma was stored at À201C prior to analysis by both methods. Sample preparation for the amino acid analyser Plasma samples, calibrators or controls (500 mL) were added to a 1.7 mL polypropylene microcentrifuge tube followed by the addition of 50 mL 35% sulphosalicylic acid. The mixture was vortex-mixed and centrifuged at 13,000 g for 5 min. After centrifugation 100 mL of supernatant was transferred to a 0.5 mL microcentrifuge tube to which 100 mL of 200 mmol/L glucosamic acid (Sigma-Aldrich, MO, USA) in Li220 diluting bu¡er was added. The tubes were mixed thoroughly at which time the samples were ready for analysis. Samples were analysed using the Beckman 6300 AAAwith a lithium cation exchange column (Pickering Laboratories, MountainView, CA, USA).
Sample preparation for ultra-performance liquid chromatography-tandem mass spectrometry
Internal standards and calibrators for ultra-performance liquid chromatography-tandem mass spectrometry
Stable isotope labelled amino acid internal standards was obtained from Cambridge Isotope Laboratories, Inc (Andover, MA, USA). The majority of which were included in labelled amino acid standards mix that was reconstituted and diluted per the manufacturer's instructions. The working internal standard was supplemented (2.5 mmol/L) with [ 2 H 10 ]alloisoleucine and [ 13 C 6 ]isoleucine also obtained from Cambridge Isotope Laboratories.The internal standards are listed inTable1.
Plasma samples, calibrators or controls (50 mL) were added to a 1.7 mL polypropylene microcentrifuge tube, containing 950 mL of methanolic working internal standards, the tubes were capped, vortex-mixed for 30 s, and centrifuged at 13,000 RPM for 3 min. After centrifugation 300 mL of the clear supernatant was transferred to a clean microcentrifuge tube and evaporated to dryness in a Savant centrifugal evaporator (10 samples take 20--30 min to completely dry down). To the dried residue, 50 mL of butanolic HCl was added, the tubes were capped, vortex-mixed for 30 s and placed in a 601C dry heat block for 20 min to facilitate derivatization. After derivatization the tubes were uncapped and again evaporated to dryness in the centrifugal evaporator. The residue was resuspended in 200 mL 50:50 mobile phases A and B (proprietary reagents, Beckman Instruments, Brea, CA, USA) and vortex-mixed for 30 s. The resuspended samples were diluted 1:50 in MilliQ s water in an autosampler vial prior to analysis.
Chromatography
Chromatographic separation was achieved using an ACQUITY s BEH C18 2.1 Â100 mm, 1.7 mm analytical column maintained at 301C and ACQUITY UPLC system (Waters Corporation, Milford, MA, USA) using a binary high pressure gradient. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in acetonitrile. The gradient pro¢le used is shown in Table 2 .
Optimum peak shape and dynamic range were achieved using 5 mL partial loop injections with a 50 mL loop. The weak needle wash was 10% methanol in water and the strong needle wash was 32% acetonitrile, 32% isopropanol, 30.8% methanol, 5% water and 0.2% formic acid. The column eluant was connected directly to the electrospray probe of the 
Mass spectrometry
Both Quattro microt API and Quattro Premiert XE tandem quadrupole mass spectrometers (Waters Corporation) were used in the positive ion electrospray mode with similar results for linearity and precision.
(Between instrument sensitivity was not evaluated in this study.) All analytes were monitored in multiple reaction monitoring (MRM) mode. Complete system control and data processing were accomplished with MassLynxt version 4.1 software. Chromatographic peaks were integrated and quanti¢ed via least squares linear regression with 1/x weighting using the supplied QuanLynxt application manager. The mass spectrometers were tuned by infusing a mixture of all seven amino acids (and their corresponding internal standards) at a concentration of 10 mg/mL via a syringe pump (10 mL/min) into a 50:50 mixture of mobile phases A and B £owing at 0.6 mL/min. Under these conditions, the mass spectrometer was optimized to provide the greatest abundance of the leucine butyl ester precursor (m/z 188.0), which is the most critical amino acid for MSUD monitoring. In MS/MS mode the collision energy for the most abundant leucine product ion (m/z 86.0) was optimized. These parameters were found to provide adequate sensitivity for all other amino acids. Typical ion source and analyser conditions are shown in Table 3 . Optimized MRM transitions were grouped temporally to optimize the mass spectrometer duty cycle for each amino acid and internal standard as shown in Table 1 .
Precision and linearity
Calibration and linearity curves and controls were made by fortifying analyte-stripped human serum obtained from Biocell Laboratories (Rancho Dominquez, CA, USA) with authentic amino acid standards. Powders of valine (Val), tyrosine (Tyr), phenylalanine (Phe), methionine (Met) and alloisoleucine (aIle) were obtained from Sigma (St Louis, MO, USA). Leucine (Leu) and isoleucine (Ile) were obtained from Fluka (Sigma-Aldrich Chemie GmbH, Switzerland). Table 4 indicates the target concentrations of each amino acid in the calibrators and controls. Within-run precision was evaluated by analysing 10 aliquots of each of the three prepared control samples within a single analytical run. Run-to-run precision was evaluated by analysing these same control samples in triplicate on ¢ve separate days.
Results
Method comparison
The results of the two methods (AAA versus LC-MS/ MS) were compared by correlation analysis where, for each amino acid, the correlation coe⁄cient (R) was greater than 0.96. Figure 1 shows the method comparison of three representative analytes, leucine, tyrosine and phenylalanine. Each of the 75 specimens was clas-si¢ed into the same PKU, MSUD or normal cohort by both methods when independently evaluated. A slight negative bias is seen for phenylalanine concentrations greater than 600 mmol/L. Figure 2 compares a normal specimen to one drawn from a patient with MSUD and one from a patient with PKU (note the presence of alloisoleucine in the MSUD specimen and its absence in the non-MSUD samples).
Linearity
All amino acids yielded linear calibration curves in the LC-MS/MS analysis over two orders of magnitude, a range which included all patients' specimens, having 3  4  5  6  1  2  3  Valine  1000  500  250  100  50  10  75  150  300  Tyrosine  400  200  100  40  20  4  30  60  120  Melhionine  1000  500  250  100  50  10  75  150  300  Alloisoleucine  100  50  25  10  5  1  7.5  15  30  Isoleucine  100  50  25  10  5  1  7.5  15  30  Leucine  2000  1000  500  200  100  20  150  300  600  Phenylalanine  2000  1000  500  200  100  20  150  300  600 r 2 values in excess of 0.99. Representative linearity curves for valine and tyrosine are as shown in Figure 3 .
Precision
Within-day and day-to-day precision for all control concentrations and all seven analytes ranged from 1.5% to 7.0% and are summarized in Table 5 .
Discussion
The measurement of amino acids has been revolutionized with the introduction of electrospray-tandem mass spectrometry. It is now possible to accurately quantitate almost all physiological amino acids using only a few microlitres of blood within a period of approximately 2 min. This technological advance has allowed for population-based screening of newborns for inherited disorders of amino acid metabolism and is now considered the standard of care in the USA and much of the developed world. The sensitivity of samples collected onto ¢lter paper is less than that from plasma samples and although perfect for screening purposes we ¢nd that plasma samples are more sensitive for patient monitoring when small changes may be clinically signi¢cant.
One consequence of the expansion in newborn screening is the detection of a greater number of a¡ected individuals putting increased pressure on metabolic diagnostic laboratories to provide management services.
One such disorder, MSUD, presents an unusual challenge in that three of the critical amino acids, leucine, isoleucine and alloisoleucine are isobaric and cannot be di¡erentiated without chromatographic separation. Traditional ion-exchange chromatography can provide this separation but this process takes up to an hour per sample for analysis and becomes prohibitive when calibrators, standards and controls also need to be run.We have developed a rapid (less than 8 min) separation protocol utilizing UPLC with mass spectrometric analysis to monitor the individual isobaric branched-chain amino acids in patients with MSUD. In a separate ongoing study of full amino acid pro¢ling using an identical analytical system, we were able to show that hydroxyproline, which is also isobaric to leucine, isoleucine and alloisoleucine does not interfere with this analysis as it does in systems that do not use a separation step (unpublished work in progress). In addition, this method also measures phenylalanine and tyrosine, which are important amino acids for monitoring patients with PKU and tyrosinaemia type 1. Methionine, which is an amino acid that is restricted in the diets of patients with homocystinuria, is also measured using the UPLC-tandem mass spectrometric system although homocystinuric patients' samples were not available for validation during the study period. The measurement of phenyalanine, tyrosine and methionine could be achieved without the need for a separation step as these are not isobaric amino acids. However, we ¢nd that having a single protocol that covers each of the amino acids that are used in long-term patient monitoring is advantageous in our practice. The manufacturer's protocol for the ion-exchange chromatographic method (AAA) requires the use of 500 mL of plasma, while the UPLC-MS/MS method required just 50 mL and maintained equivalent sensitivity providing additional advantage for this methodology since sample volumes from paediatric patients need to be as small as possible given the smaller total blood volume in children. The AAA methodology is generally regarded as a'gold standard' method that has performed well in the College of American Pathologists pro¢ciency testing programme since its inception. The UPLC-MS/MS method has not yet been tested in a pro-¢ciency programme but exhibits excellent linearity over the clinical reporting range of plasma concentrations, is precise and compares favourably with existing ion-exchange chromatographic techniques.
